Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Intellia Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics: A Promising Buy Rating Supported by Trial Success and Strong Financials
Analysts' Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
Intellia Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Intellia Therapeutics (NTLA) Gets a Buy From Truist Financial
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)